Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.30 Consensus Price Target from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been given an average recommendation of “Hold” by the five research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $7.30.

Several equities analysts have recently weighed in on ESPR shares. HC Wainwright restated a “buy” rating on shares of Esperion Therapeutics in a research report on Friday, January 10th. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective for the company.

Esperion Therapeutics Trading Down 2.2 %

Shares of Esperion Therapeutics stock opened at $2.21 on Friday. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94. The firm has a market capitalization of $435.46 million, a PE ratio of -3.45, a P/E/G ratio of 0.17 and a beta of 1.03. The firm’s 50-day moving average price is $2.47 and its 200 day moving average price is $2.18.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. BOKF NA acquired a new stake in Esperion Therapeutics during the second quarter worth about $26,000. Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at approximately $27,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $28,000. National Bank of Canada FI raised its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares during the period. Finally, Versor Investments LP acquired a new position in Esperion Therapeutics in the third quarter valued at approximately $44,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.